Zacks Investment Research downgraded shares of Diasorin (OTCMKTS:DSRLF) from a strong-buy rating to a hold rating in a research note published on Tuesday.
According to Zacks, “DiaSorin S.p.A. engages in the development, production and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which serves infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology clinical areas. DiaSorin S.p.A. is headquartered in Vercelli, Italy. “
Shares of Diasorin (OTCMKTS DSRLF) remained flat at $$90.94 during midday trading on Tuesday. Diasorin has a 1-year low of $54.86 and a 1-year high of $93.25.
ILLEGAL ACTIVITY WARNING: “Diasorin (DSRLF) Lowered to “Hold” at Zacks Investment Research” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://ledgergazette.com/2017/12/06/diasorin-dsrlf-lowered-to-hold-at-zacks-investment-research.html.
Diasorin Company Profile
DiaSorin S.p.A. engages in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in various clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; gastrointestinal infections; autoimmunity; and cardiac and brain damages.
Receive News & Ratings for Diasorin Spa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diasorin Spa and related companies with MarketBeat.com's FREE daily email newsletter.